Home LiteratureArticle Details
PMID: 1918364 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Differential protease expression by cutaneous squamous and basal cell carcinomas.

The Journal of clinical investigation ·Vol. 88 ·No. 4 ·1991-10-00 ·Pages 1073-9

Sappino AP, Belin D, Huarte J, Hirschel-Scholz S, Saurat JH, Vassalli JD

Abstract

To assess the postulated role of plasminogen activation in tumor invasion, we have investigated the cellular sites of synthesis for urokinase-type (uPA) and tissue-type (tPA) plasminogen activators and their inhibitors (PAI-1 and PAI-2) in two human cutaneous neoplasia that differ in their metastatic potential. The combined use of zymography on tissue sections and in situ hybridization demonstrates that uPA is produced by malignant cells of squamous cell carcinomas (SCC) but not by basal cell carcinomas (BCC), whereas tPA is detected exclusively in nonmalignant dermal tissue. In addition, we show that SCC neoplastic cells simultaneously produce variable amounts of PAI-1, and that PAI-1 production correlates inversely with uPA enzymatic activity. These observations establish that invasive human malignant cells in vivo can activate plasminogen through uPA production during the early phases of tumor growth; they also demonstrate that the proteolytic activity of tumor cells can be modulated by the concomitant production of PAI-1. Because SCC have a higher invasive and metastatic potential than BCC, our findings lend further support to the involvement of plasminogen activation in malignant behavior.

MeSH Terms
Carcinoma, Basal Cell/enzymology Carcinoma, Squamous Cell/enzymology Humans Neoplasm Metastasis Plasminogen Inactivators/analysis RNA, Messenger/analysis Skin Neoplasms/enzymology Tissue Plasminogen Activator/biosynthesis,genetics Urokinase-Type Plasminogen Activator/biosynthesis,genetics
Chemicals
Plasminogen Inactivators RNA, Messenger Tissue Plasminogen Activator Urokinase-Type Plasminogen Activator
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Sappino A P
Division of Onco-Haematology, University of Geneva Medical School, Switzerland.
Belin D
Huarte J
Hirschel-Scholz S
Saurat J H
Vassalli J D
References (38)
38 references, click to expand
  1. In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase.
    J Cell Biol. 1988 Dec;107(6 Pt 1):2437-45 PMID: 2848851
  2. Plasminogen activators, plasminogen activator inhibitors and procoagulant analyzed in twenty human tumor cell lines.
    Int J Cancer. 1986 Nov 15;38(5):719-27 PMID: 3490446
  3. Migrating keratinocytes express urokinase-type plasminogen activator.
    J Invest Dermatol. 1987 Apr;88(4):418-23 PMID: 2435817
  4. Amiloride selectively inhibits the urokinase-type plasminogen activator.
    FEBS Lett. 1987 Apr 6;214(1):187-91 PMID: 3106085
  5. Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas.
    Cancer Res. 1987 Aug 1;47(15):4043-6 PMID: 2440556
  6. Plasminogen activator dependent pathways in the dissemination of human tumor cells in the chick embryo.
    Cell. 1988 Feb 12;52(3):321-8 PMID: 3125981
  7. Immunohistochemical localization of urokinase- and tissue-type plasminogen activators in psoriatic skin.
    J Invest Dermatol. 1987 Jan;88(1):28-32 PMID: 3098860
  8. Proteolytic enzymes in cancer invasion and metastasis.
    Semin Thromb Hemost. 1986 Oct;12(4):294-307 PMID: 3024322
  9. Plasminogen activator inhibitor type-1: reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing.
    FEBS Lett. 1986 Dec 15;209(2):213-8 PMID: 3025016
  10. Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation.
    Cancer Res. 1990 Aug 1;50(15):4676-84 PMID: 2114945
  11. The EGF/TGF alpha receptor in skin.
    J Invest Dermatol. 1990 Jun;94(6 Suppl):164S-170S PMID: 2191051
  12. Plasminogen activator inhibitors: hormonally regulated serpins.
    Mol Cell Endocrinol. 1990 Jan 2;68(1):1-19 PMID: 2105900
  13. Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney.
    J Clin Invest. 1991 Mar;87(3):962-70 PMID: 1900311
  14. Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes.
    Cancer Res. 1990 Dec 1;50(23):7623-33 PMID: 1701350
  15. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer.
    Cancer Res. 1990 Nov 1;50(21):6827-9 PMID: 2119883
  16. Regulation by epidermal growth factor of human squamous cell carcinoma plasminogen activator-mediated proteolysis of extracellular matrix.
    Cancer Res. 1989 Jun 15;49(12):3302-9 PMID: 2497975
  17. Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors.
    Cancer Res. 1989 Dec 15;49(24 Pt 1):6960-5 PMID: 2555056
  18. Plasminogen activators in tissue remodeling and invasion: mRNA localization in mouse ovaries and implanting embryos.
    J Cell Biol. 1989 Nov;109(5):2471-9 PMID: 2509486
  19. Identification and primary sequence of an unspliced human urokinase poly(A)+ RNA.
    Proc Natl Acad Sci U S A. 1984 Aug;81(15):4727-31 PMID: 6589620
  20. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells.
    Proc Natl Acad Sci U S A. 1983 May;80(10):2956-60 PMID: 6574465
  21. Antibodies to plasminogen activator inhibit human tumor metastasis.
    Cell. 1983 Dec;35(3 Pt 2):611-9 PMID: 6418388
  22. Protease-nexin: a cellular component that links thrombin and plasminogen activator and mediates their binding to cells.
    Cell. 1980 Aug;21(1):37-45 PMID: 6157479
  23. Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme-inhibitor complex.
    Proc Natl Acad Sci U S A. 1983 Nov;80(22):6804-8 PMID: 6580616
  24. The induction of differentiation in teratocarcinoma stem cells by retinoic acid.
    Cell. 1978 Oct;15(2):393-403 PMID: 214238
  25. Urokinase- and tissue-type plasminogen activators in keratinocytes during wound reepithelialization in vivo.
    J Invest Dermatol. 1988 Jun;90(6):790-5 PMID: 3131440
  26. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase.
    J Cell Biol. 1985 Jan;100(1):86-92 PMID: 3880760
  27. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes.
    Proc Natl Acad Sci U S A. 1985 Aug;82(15):4939-43 PMID: 2991901
  28. Plasminogen activators, tissue degradation, and cancer.
    Adv Cancer Res. 1985;44:139-266 PMID: 2930999
  29. Modulation of urokinase plasminogen activator gene expression during the transition from quiescent to proliferative state in normal mouse cells.
    EMBO J. 1986 May;5(5):855-61 PMID: 2424752
  30. Increase in urokinase plasminogen activator mRNA synthesis in human carcinoma cells is a primary effect of the potent tumor promoter, phorbol myristate acetate.
    J Cell Biol. 1986 Apr;102(4):1235-41 PMID: 3958045
  31. Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade.
    Cell. 1986 Nov 21;47(4):487-98 PMID: 3022933
  32. Isolation and characterization of the human tissue-type plasminogen activator structural gene including its 5' flanking region.
    J Biol Chem. 1985 Sep 15;260(20):11223-30 PMID: 3161893
  33. Cathepsin D: an independent prognostic factor for metastasis of breast cancer.
    Lancet. 1989 Nov 11;2(8672):1115-8 PMID: 2572846
  34. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture.
    J Cell Biol. 1989 Jul;109(1):309-15 PMID: 2526131
  35. Facultative polypeptide translocation allows a single mRNA to encode the secreted and cytosolic forms of plasminogen activators inhibitor 2.
    EMBO J. 1989 Nov;8(11):3287-94 PMID: 2583099
  36. Detection of transforming growth factor alpha in normal, malignant, and hyperproliferative human keratinocytes.
    J Exp Med. 1988 Feb 1;167(2):670-5 PMID: 3279155
  37. Isolation of a new specific plasminogen activator inhibitor from pregnancy plasma.
    Br J Haematol. 1986 Feb;62(2):221-8 PMID: 3484964
  38. Proteinases and extracellular matrix remodeling.
    Curr Opin Cell Biol. 1989 Oct;1(5):974-82 PMID: 2697298
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
0021-9738
Published
1991-10-00
Pages
1073-9
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC295554
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]